ArticleFrontiers in medicine2025
Localized and historical hypermobile spectrum disorders share self-reported symptoms and comorbidities with hEDS and HSD.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- An Online Pilates Program for People with Hypermobility: A Pragmatic Clinical Trial Looking at Function, Interoception, Kinesiophobia, and Physical Activity Levels.Journal of multidisciplinary healthcare · 2026Trial
- Prevalence of Intracranial and Cervical Artery Abnormalities in Patients with Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders Presenting to an Academic Headache Clinic.Neurology international · 2026Article
- Sex differences in self-reported symptoms and comorbidities associated with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders: A retrospective study.Research square · 2026Article
- Females with hypermobile Ehlers-Danlos syndrome self-report more sexual problems than chronic pain controls without hypermobility, males, or patients with hypermobile spectrum disorders.Frontiers in reproductive health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Background: In 2017 a revised clinical criterion for the diagnosis of hypermobile Ehlers-Danlos syndrome (hEDS) was proposed in order to better distinguish hEDS from other joint hypermobility disorders which are termed hypermobility spectrum disorders (HSD). The goal of this study was to determine whether patients with localized HSD (L-HSD) or historical HSD (H-HSD) differed in 100 symptoms/comorbidities from controls and/or patients diagnosed with hEDS or HSD. Methods: In this study, we examined 100 self-reported symptoms/comorbidities from 2,695 patients diagnosed with hEDS, HSD, L-HSD/H-HSD, or controls. Results: From November 1, 2019, to August 27, 2024, 2,695 patients filled out an Intake Questionnaire at the Mayo Clinic Florida EDS Clinic. Using the 2017 diagnostic criterion, 60.6% ( Conclusion: We found that patients with L-HSD/H-HSD had many symptoms and comorbidities that closely resembled HSD suggesting that revised diagnostic criteria for hEDS and HSD should include L-HSD/H-HSD within a diagnosis of HSD. Additionally, our data further suggest that patients with HSD (including L-HSD/H-HSD) have more symptoms/comorbidities than patients with hEDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.